ASCO25: MSD’s ADC candidate achieves 56.3% ORR in lymphoma trial
Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma (DLBCL), …
Post
-
-
ASCO25: Pfizer’s Braftovi combo boasts 47% drop in disease progression in mCRC
Pfizer’s Braftovi (encorafenib) combination therapy was shown to reduce the risk of death by nearly half compared to standard of …
-
Auron doses first subject in AUTX-703 trial for haematologic malignancies
Auron Therapeutics has dosed the first subject in the multicentre Phase I trial of the orally available lysine acetyltransferase 2A …
-
ASCO25: Merck KGaA’s ADC shows safety and tolerability in colorectal cancer trial
Merck KGaA’s antibody-drug conjugate (ADC), precemtabart tocentecan, has shown to be safe and tolerable in a Phase Ib trial. The ongoing …
-
Biohaven initiates Phase II/III trial of BHV-8000 for early Parkinson’s
Biohaven has commenced a randomised Phase II/III trial of the tyrosine kinase 2 (TYK2) / Janus Kinase 1 (JAK1) inhibitor, …
-
Astellas and Evopoint sign ADC licensing deal
Astellas Pharma has signed an exclusive licensing agreement with Evopoint Biosciences for XNW27011, a Claudin18.2 (CLDN18.2)-targeting clinical-stage antibody-drug conjugate (ADC). Astellas …
-
Intellia stock dips following safety event in Phase III gene therapy trial
Intellia Therapeutics’ stock has fallen nearly 23% following an announcement that a patient in its Phase III trial for a …
-
Alumis concludes enrolment in Phase III programme of plaque psoriasis therapy
Alumis has concluded enrolment in its pivotal Phase III ONWARD programme, aimed to assess the safety and efficacy of the …
-
Sibeprenlimab’s priority review highlights potential to differentiate in IgAN space
Otsuka Pharmaceuticals recently announced that the FDA has accepted for review the biologics licence application (BLA) for sibeprenlimab. Sibeprenlimab acts …
-
Entrada’s Phase I/II trial of DMD treatment authorised to begin in EU
Entrada Therapeutics has secured the Health Authorities and Ethics Committees' authorisation within the European Union (EU) Clinical Trial Regulation to …
-
Pfizer and Arvinas gamble to shift breast cancer treatment paradigm
Breast cancer (BC) is the most prevalent cancer among women globally with two million diagnosed cases each year. Oestrogen receptor …
-
Patient-centric approaches thrive on wearables and remote access in trials
A transformative application of artificial intelligence (AI) in drug development lies in its potential to match the right patient population …
-
GSK and Spero halt UTI antibiotic trial early due to high efficacy
GSK and Spero Therapeutics’ Phase III trial of their oral antibiotic for complicated urinary tract infections (cUTI) will end early …
-
WCG launches integrated solution to enhance clinical trial process
WCG has launched the WCG Study Accelerator, an integrated solution designed to optimise the clinical trial process and enhance outcomes …
-
ASCO 2025: Merus wins in head-to-head with Bicara for head and neck cancer
22 May 2025 saw the announcement that two highly anticipated trials would have presentations at the 2025 Annual Meeting of …
